Skip to main content
FERMENTA BIOTECH LIMITED logo

FERMENTA BIOTECH LIMITED — Investor Relations & Filings

Ticker · FERMENTA ISIN · INE225B01021 LEI · 335800VNTNWW8G1U9314 BSE.NS Manufacturing
Open in API
Filings indexed 671 across all filing types
Latest filing 2020-02-24 Regulatory Filings
Country IN India
Listing BSE.NS FERMENTA

About FERMENTA BIOTECH LIMITED

https://fermentabiotech.com

Fermenta Biotech Limited is a specialized biotechnology company primarily focused on the development and manufacture of Vitamin D3 (Cholecalciferol). As one of the few vertically integrated manufacturers globally, the company produces Vitamin D3 for diverse applications, including pharmaceuticals, dietary supplements, human nutrition, and animal feed. Beyond its core Vitamin D3 portfolio, the company offers a range of specialty enzymes, particularly for the synthesis of beta-lactam antibiotics, and provides environmental solutions through its biotechnology expertise. Fermenta Biotech emphasizes high-quality standards, maintaining various international certifications for its manufacturing facilities. Its product offerings extend to premixes and value-added formats designed to meet specific formulation requirements. The company serves a global clientele, leveraging its research and development capabilities to innovate in the fields of nutrition and biotechnology.

Recent filings

Filing Released Lang Actions
Intimation of Schedule of Analysts / Institutional Investors meeting under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 Pursuant to the relevant provisions ....
Regulatory Filings Classification · 95% confidence The document is a short notice informing the stock exchange (BSE Limited) about a scheduled meeting with analysts and institutional investors. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and mentions that an investor presentation will be shared during the interaction, which is available on the exchange's website. The document explicitly states it is an intimation of the schedule of an investor meeting and does not contain the presentation itself or detailed financial data. The length is only 1910 characters, indicating it is a brief announcement rather than a full report. Therefore, this document fits the category of Investor Presentation (IP) announcement or related notice. However, since the document itself is the intimation of the meeting and the presentation is referenced as available elsewhere, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about the meeting and presentation availability, not the presentation document itself.
2020-02-24 English
Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company will be interacting ....
Investor Presentation Classification · 90% confidence The document is a short notice informing about a scheduled meeting with analysts and institutional investors, referencing SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. It mentions that an investor presentation will be shared during the interaction and is available on the BSE website. The document does not contain any financial data or detailed report content but serves as an announcement of the upcoming investor presentation meeting. Given the length (1927 characters) and content, it fits the category of an Investor Presentation announcement rather than the presentation itself. However, since it is primarily an intimation about the schedule and availability of the presentation, the best classification is Investor Presentation (IP).
2020-02-20 English
Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby enclose a copy of Investor Relations Presentation for February ....
Investor Presentation Classification · 95% confidence The document is titled as an "Investor Relations Presentation" dated February 2020 and is addressed to the stock exchange (BSE Limited). It explicitly states it is an "Investor Relations Presentation" and contains detailed company information including business strategy, product portfolio, R&D, accreditations, financial updates for 9MFY20, and future outlook. The document is about 15,000 characters long, which is consistent with a detailed presentation rather than a brief announcement. There is no indication that this is a full annual or quarterly report, audit report, or earnings release. It is clearly a presentation prepared for investors, focusing on company strategy, market position, and financial highlights. Therefore, the appropriate classification is Investor Presentation (IP).
2020-02-19 English
This is to inform you that pursuant to members' approval by way of postal ballot including e-voting dated January 28, 2020, the Business Restructuring Committee of the Board of Directors ....
Share Issue/Capital Change Classification · 100% confidence The document is a formal letter addressed to the stock exchange (BSE Limited) informing about the allotment of bonus equity shares following members' approval. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content details the share capital changes due to the bonus shares allotment, including pre- and post-bonus share capital figures. The document is an announcement of a capital change event, specifically the allotment of bonus shares, rather than a full financial report or other types of filings. The document length is short (2364 characters), and it is clearly an announcement rather than a report or presentation. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2020-02-15 English
Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation to our intimation given vide ....
Regulatory Filings
2020-02-14 English
Pursuant to Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 and subject to the provisions of the SEBI (Share Based Employee Benefits) Regulations, ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to the stock exchange (BSE Limited) disclosing the grant of stock options to employees under an ESOP scheme. It references compliance with SEBI regulations and provides detailed information about the options granted, including number, pricing, vesting, and exercise terms. The document is a disclosure of an event or information under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to material events or information that must be disclosed to the stock exchange. It is not a full financial report, audit, earnings release, or any other report type but a regulatory disclosure about share-based employee benefits. The document length is 3240 characters, which is relatively short and is a direct disclosure letter rather than a report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and disclosures that do not fit other specific categories.
2020-02-12 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.